Table 1.
Characteristics of cervical cancer patients in training and external test cohorts.
| Characteristic | Training cohort | Test cohort | ||||
|---|---|---|---|---|---|---|
| LVSI- | LVSI+ | P | LVSI- | LVSI+ | P | |
| Age | 51.63 ± 10.84 | 51.35 ± 10.49 | 0.853 | 51.81 ± 8.73 | 49.06 ± 10.52 | 0.156 |
| Maximum diameter | 22.94 ± 11.66 | 34.31 ± 12.75 | <0.001 | 3.14 ± 1.45 | 3.85 ± 1.12 | 0.007 |
| Histological type | 0.161 | 0.717 | ||||
| Squamous cell carcinoma | 64 (68.09) | 83 (79.81) | 36 (75.00) | 43 (79.63) | ||
| Adenocarcinoma | 24 (25.53) | 16 (15.38) | 8 (16.67) | 6 (11.11) | ||
| Adenosquamous carcinoma | 6 (6.38) | 5 (4.81) | 4 (8.33) | 5 (9.26) | ||
| Degree of cellular differentiation | <0.001 | 0.737 | ||||
| Low | 10 (10.64) | 21 (20.19) | 11 (22.92) | 16 (29.63) | ||
| Middle | 68 (72.34) | 82 (78.85) | 23 (47.92) | 23 (42.59) | ||
| High | 16 (17.02) | 1 (0.96) | 14 (29.17) | 15 (27.78) | ||
| HPV | 0.275 | 0.868 | ||||
| Negative | 48 (51.06) | 44 (42.31) | 15 (31.25) | 15 (27.78) | ||
| Positive | 46 (48.94) | 60 (57.69) | 33 (68.75) | 39 (72.22) | ||
| CA125 | 0.046 | 0.481 | ||||
| ≤35 | 79 (84.04) | 74 (71.15) | 36 (75.00) | 36 (66.67) | ||
| >35 | 15 (15.96) | 30 (28.85) | 12 (25.00) | 18 (33.33) | ||
| CA199 | 0.878 | 0.456 | ||||
| ≤27 | 75 (79.79) | 81 (77.88) | 37 (77.08) | 37 (68.52) | ||
| >27 | 19 (20.21) | 23 (22.12) | 11 (22.92) | 17 (31.48) | ||
| SCC | 0.622 | 0.582 | ||||
| ≤1.5 | 44 (46.81) | 44 (42.31) | 24 (50.00) | 23 (42.59) | ||
| >1.5 | 50 (53.19) | 60 (57.69) | 24 (50.00) | 31 (57.41) | ||
| FIGO stage | 0.001 | 0.04 | ||||
| I | 63 (67.02) | 47 (45.19) | 29 (60.42) | 22 (40.74) | ||
| II | 29 (30.85) | 43 (41.35) | 15 (31.25) | 18 (33.33) | ||
| III | 2 (2.13) | 14 (13.46) | 4 (8.33) | 14 (25.93) | ||
CEA, carcinoembryonic antigen; CA125, carbohydrate antigen 125; CA19-9, carbohydrate antigen 19-9; HPV, Human papillomavirus; FIGO, International Federation of Gynecology and Obstetrics; SCC, Squamous cell carcinoma antigen.